FDA
-
-
-
-
-
-
-
Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting
-
-
-
-
-
-
-
Fate Therapeutics selected for FDA manufacturing pilot program
-
-
-
-
-
-
-
Biotechnology: Here are Piper Sandler's Top Picks and Focus Names for 2026
-
-
-
-
-
-
-
Fate Therapeutics (FATE) PT Lowered to $2.20 at BofA Securities
-
-
-
-
-
-
-
Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
-
-
-
-
-
-
-
Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
-
-
-
-
-
-
-
GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities
-
325,254 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

